headaches with semaglutide What is the cause and recommended management of headache in a patient who has recently initiated therapy? GLP 1 Headache: Causes, Tips

The following sources give you the unfiltered picture - clinical evidence, regulatory context, and safety data straight from the organizations that publish it: FDA.gov - official FDA communications on compounded semaglutide, tirzepatide, and the 503B Bulks List proposal (April 30, 2026)

These outcomes were obtained from linked electronic health records in national health registries

The genetic test reveals predispositions in peptide-related pathways, not exact medication response or guarantee of semaglutide efficacy

Clinical trials demonstrate 24% body weight reduction at 48 weeks with the 12mg dose, compared to 14.9% for semaglutide and 22.5% for tirzepatide at equivalent study durations

Implications for employers: This study is consistent with other studies of GLP-1 medications for both diabetes and obesity demonstrating substantial cardiovascular and metabolic benefits of this class of medications

Through a subgroup analysis based on the specific drug, the results revealed that none of the six GLP-1RA drugs examined generated a safety signal in relation to suicide or self-injury